- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Reference Prices May Have Limited Potential for Savings, Report Says
Reference prices, a health benefit strategy that requires patients to pay costs above a set price, may save employers and patients money, but their potential may be limited-perhaps even more so under the Patient Protection and Affordable Care Act.
Reference prices, a health benefit strategy that requires patients to pay costs above a set price, may save employers and patients money, but their potential may be limited—perhaps even more so under the Patient Protection and Affordable Care Act.
The California Public Employees' Retirement System and WellPoint subsidiary Anthem adopted a $30,000 reference price for scheduled hip and knee surgeries in 2011. The switch saved CalPERS $2.8 million that year and prompted some hospitals to drop their prices to be competitive, according to a newly released paper by the Center for Studying Health System Change.
But it may be difficult to repeat those results elsewhere, wrote the center's Amanda Lechner, Rebecca Gourevitch and Paul Ginsburg. Meanwhile, the financial incentive that reference prices create to avoid high-priced hospitals may be undermined by the Affordable Care Act.
Read the full story here: http://bit.ly/1kjemmn
Source: Modern Healthcare
Review Emphasizes Potential Infection Risks With BTK Inhibitors
November 2nd 2024Although Bruton tyrosine kinase (BTK) inhibitor monotherapy in chronic lymphocytic leukemia (CLL) has been a game-changer, patients have significantly increased risks of infection, especially in the upper respiratory tract.
Read More
Sustaining Compassionate Trauma Care Across Communities
September 30th 2024September is National Recovery Month, and we are bringing you another limited-edition month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. In our final episode, we speak with Lyndra Bills, MD, and Shari Hutchison, MS.
Listen
PAH Treatment Outcomes Similar Regardless of Diagnosis Time
November 1st 2024The study findings underscore the importance of early initiation of macitentan and tadalafil among patients who have pulmonary arterial hypertension (PAH), and represent a shift in understanding of prognosis based on diagnosis timing.
Read More
